title: Salmon calcitonin induces pituitary tumor in rats.
abstract: Calcitonin is widely used in the treatment of post-menopausal osteoporosis. The present study was designed to investigate the effects of salmon calcitonin (SCT) on the incidence of the pituitary tumors in Sprague-Dawley (SD) rats. Subcutaneous injections of SCT at a dose of 160 IU/kg/day for 6 months reduced body weight and induced one pituitary hyperplasia and three pituitary adenomas in 4 of 5 animals, while 5 controls did not show any changes. Prolactin-positive cells were located at the periphery of the affected pituitaries adjacent to the prolactin-negative adenomas. In addition, serum concentrations of prolactin and TSH were lower than in the controls, although serum calcium or LH levels were not significantly different from the controls. Among 7 animals treated with SCT for 6 months followed by no medication for another 6 months, 5 adenomas were detected, one of which had invasive growth toward the adjacent tissue, whereas only one adenoma was found in 9 controls. These results suggest that SCT administration at a high dose may induce the formation of pituitary adenoma, or may accelerate the development of spontaneous pituitary adenomas, some of which show frequent mitotic figures and invasive growth into the surrounding tissue, possibly resulting in malignant transformation. This indicates the need for caution in considering whether calcitonin injections into patients with osteoporosis as well as Paget's disease may induce such pituitary tumors.
authors.affiliation: Fourth Department of Medicine, Saitama Medical School, Japan.
authors.forename: J
authors.initials: J
authors.lastname: Ishii
authors.forename: S
authors.initials: S
authors.lastname: Katayama
authors.forename: A
authors.initials: A
authors.lastname: Itabashi
authors.forename: M
authors.initials: M
authors.lastname: Takahama
authors.forename: S
authors.initials: S
authors.lastname: Kawazu
mesh_terms: D000236:Adenoma / Q000097:blood / Q000139:chemically induced*; D000818:Animals; D002116:Calcitonin / Q000008:administration & dosage / Q000009:adverse effects*; D002118:Calcium / Q000097:blood; D004305:Dose-Response Relationship, Drug; D007279:Injections, Subcutaneous; D007986:Luteinizing Hormone / Q000097:blood; D008297:Male; D009929:Organ Size / Q000187:drug effects; D010902:Pituitary Gland / Q000737:chemistry / Q000187:drug effects / Q000473:pathology; D010911:Pituitary Neoplasms / Q000097:blood / Q000139:chemically induced*; D011388:Prolactin / Q000032:analysis / Q000097:blood; D011863:Radioimmunoassay; D051381:Rats; D011919:Rats, Inbred Strains; D013972:Thyrotropin / Q000097:blood
chemical_list: C028815:salmon calcitonin; D011388:Prolactin; D007986:Luteinizing Hormone; D013972:Thyrotropin; D002116:Calcitonin; D002118:Calcium